Physician profile
Ana Ivanova
NPI 1104812833
$671.09
in general payments reported to CMS, 2019-2025
13 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $30.07 · 2022: $67.66 · 2023: $143 · 2024: $71.22 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $370.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $293.47 | 2019-2025 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $65.22 | 2019-2020 | |
| Abbott Laboratories | $59.35 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $56.63 | 2019-2023 | Eliquis |
| Abbvie INC. | $38.20 | 2022-2023 | |
| Medtronic, INC. | $33.79 | 2024 | Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.47 | 2023 | Jardiance |
| Sanofi Pasteur INC. | $19.76 | 2019 | |
| Glaxosmithkline, LLC. | $18.97 | 2025 | Shingrix, Arexvy |
| Pfizer INC. | $17.68 | 2022 | |
| Amarin Pharma, INC. | $17.24 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Ivanova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.